Unknown

Dataset Information

0

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.


ABSTRACT: Trastuzumab, an anti-ErbB2 humanized antibody, brings benefit to patients with ErbB2-amplified metastatic breast cancers. However, the resistance to trastuzumab is common. Our previously reported H2-18, an anti-ErbB2 antibody, potently induced programmed cell death in trastuzumab-resistant breast cancer cells. Here, we aim to investigate the antitumor efficacy of H2-18 in combination with the pan-PI3K inhibitor GDC-0941 in trastuzumab-resistant breast cancer cell lines. The results showed that H2-18 and GDC-0941 synergistically inhibited the in vitro proliferation of BT-474, SKBR-3, HCC-1954 and HCC-1419 breast cancer cells. H2-18 plus GDC-0941 showed significantly enhanced programmed cell death-inducing activity compared with each drug used alone. The combination of H2-18 and GDC-0941 did not increase the effect of single agent on ROS production, cell cycle and ErbB2 signaling. Importantly, the in vivo antitumor efficacy of H2-18 plus GDC-0941 was superior to that of single agent. Thus, the enhanced in vivo antitumor efficacy of H2-18 plus GDC-0941 may mainly be attributable to its increased programmed cell death-inducing activity. Collectively, H2-18 plus GDC-0941 could effectively inhibit tumor growth, suggesting the potential to be translated into clinic as an efficient strategy for ErbB2-overexpressing breast cancers.

SUBMITTER: Wang L 

PROVIDER: S-EPMC5581078 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.

Wang Lingfei L   Yu Xiaojie X   Wang Chao C   Pan Shujun S   Liang Beibei B   Zhang Yajun Y   Chong Xiaodan X   Meng Yanchun Y   Dong Jian J   Zhao Yirong Y   Yang Yang Y   Wang Huajing H   Gao Jie J   Wei Huafeng H   Zhao Jian J   Wang Hao H   Hu Chaohua C   Xiao Wenze W   Li Bohua B  

Oncotarget 20170516 32


Trastuzumab, an anti-ErbB2 humanized antibody, brings benefit to patients with ErbB2-amplified metastatic breast cancers. However, the resistance to trastuzumab is common. Our previously reported H2-18, an anti-ErbB2 antibody, potently induced programmed cell death in trastuzumab-resistant breast cancer cells. Here, we aim to investigate the antitumor efficacy of H2-18 in combination with the pan-PI3K inhibitor GDC-0941 in trastuzumab-resistant breast cancer cell lines. The results showed that H  ...[more]

Similar Datasets

| S-EPMC7988693 | biostudies-literature
| S-EPMC4287394 | biostudies-literature
| S-EPMC4359256 | biostudies-literature
| S-EPMC3292793 | biostudies-literature
| S-EPMC6057974 | biostudies-literature
| S-ECPF-GEOD-20719 | biostudies-other
| S-EPMC9208486 | biostudies-literature
| S-EPMC3984329 | biostudies-literature
2010-05-25 | GSE20719 | GEO
| S-EPMC6877939 | biostudies-literature